Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Goldshield Recalls Single Batch Of Venaxx XL Due To Missing Patient Information Leaflet
Goldshield Pharmaceuticals Limited is recalling a single batch of Venaxx XL 75mg prolonged release capsules. This is due to the absence of the Patient Information Leaflet (PIL) in all packs in the batch number 0100524. Venaxx XL contains the active ingredient venlafaxine and is used in the treatment of depression and anxiety disorders. Please note that there are other venlafaxine products available, but this alert only affects the Venaxx 75mg XL prolonged release capsules. For more information please visit: http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON123323
Learn More

MHRA Warns Healthcare Professionals about Increased Risk Of Bladder Cancer With Pioglitazone
The Medicines and Healthcare products Regulatory Agency (MHRA) has notified healthcare professionals of a small increase in the risk of bladder cancer associated with pioglitazone (Actos, Competact) use. It is not clear if the risk increases early in treatment or only after prolonged use. In light of these findings, the MHRA recommends that pioglitazone should not be used in patients with a history of bladder cancer, or in patients with uninvestigated blood in the urine. Prescribers are also advised to review the safety and effectiveness of pioglitazone in individuals after a treatment period of 3 to 6 months to ensure that only patients who are benefiting continue to be treated. Pioglitazone (Actos) is used in the control of type 2 diabetes. It is also available as a tablet in combination with metformin (Competact). For further information please visit: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON123285
Learn More

Date Published Title Medicine Source
2011-07-29 Goldshield Recalls Single Batch Of Venaxx XL Due To Missing Patient Information Leaflet Venlafaxine MHRA
2011-07-25 MHRA Warns Healthcare Professionals about Increased Risk Of Bladder Cancer With Pioglitazone Pioglitazone and Metformin MHRA
2011-07-12 MHRA Issues Reminder about the Addiction Risk with OTC Codeine-Containing Medicines Paracetamol/Codeine MHRA
2011-07-12 MHRA Issues Reminder About Addiction Risk With Benzodiazepines Lorazepam MHRA
2011-07-12 MHRA Lifts Licence Suspension For Octagam Octagam MHRA
2011-07-12 Healthcare Professionals Advised Not To Use Dexrazoxane In Children Dexrazoxane MHRA
2011-07-11 Ranbaxy Recalls Isotretinoin 20mg Capsules Isotretinoin MHRA
2011-07-07 New Study Found Slight Increased Risk of Atrial Fibrillation or Flutter With Use of NSAIDs and COX-2 Inhibitors Tiaprofenic Acid MediGuard CRT
2011-07-05 Janssen-Cilag Discontinues Regranex Gel Becaplermin Manufacturer
2011-06-29 New Study Suggests High-Dose Statins May Cause Diabetes Simvastatin MediGuard CRT
2011-06-29 New Study: Combining Commonly Used Drugs Linked to a Greater Risk of Death and Declining Brain Function Beclometasone MediGuard CRT
2011-06-22 Bayer Recalls Canesten Pessary Due To Patient Information Leaflet Error Clotrimazole MHRA
2011-06-07 Healthcare Professionals Advised Of Latest Evidence On Blood Clot Risk With Yasmin Drospirenone with Ethinyl Estradiol MHRA
2011-06-07 Healthcare Professionals Advised Of Potential Risk Of Atypical Fractures of the Thigh With Bisphosphonates Ibandronic Acid MHRA
2011-06-07 Update on the Recommended Doses Of Paracetamol Liquid For Children Paracetamol MHRA
2011-06-03 Increased Risk of Blood Clots With Vivaglobin Immunoglobulin Manufacturer
2011-06-03 Bausch & Lomb Recall Single Batch of Minims Dexamethasone Eye Drops Dexamethasone MHRA
2011-06-03 Thyrogen In Short Supply Thyrotropin Alfa Manufacturer
2011-06-03 CIS Bio Issues Further Side Effect Information For Scintimun Tigecycline Manufacturer
2011-06-03 Zerit Use Restricted Due To Side Effects Stavudine Manufacturer